Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly

Abstract

Background: Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin lymphoma confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of methotrexate, procarbazine, and lomustine (R-MCP). Design and methods: PCNSL patients ≥ 65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m 2 i.v. on days -6, 1, 15, and 29), methotrexate (3 g/m 2 i.v., days 2, 16, and 30) followed by folinic rescue, procarbazine (60 mg/m 2 orally, days 2-11), and lomustine (110 mg/m 2 orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were overall survival (OS) and progression-free survival (PFS). Results: Twenty-eight patients were included (median age 75, median KPS 60%). Best documented response: complete remission in 18 of 28 (64%), partial remission in 5 of 28 (18%), stable disease in 1 of 28 (4%), and progressive disease in 2 of 28 (7%) patients. Response was not assessed in two patients. Two treatment-associated deaths were observed. After a median follow-up of 36 months, the 3-year PFS and OS was 31%. Conclusion: R-MCP regimen is well tolerated and active in elderly patients with newly diagnosed PCNSL. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.